Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Feb 13, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $6.492B. Analysts estimated a revenue of $6.260B. The revenues were 3.71% above the estimates. Earnings per share were $1.38. The reported EPS was above estimates by 1.47%. Analysts had estimated an EPS of $1.36.
In a different note, On Feb 10, 2017, Mizuho said it Downgrades its rating on Teva Pharmaceutical Industries Ltd (ADR). According to the research note, Mizuho Lowers the price target to $27 per share from a prior target of $40. The shares have been rated ‘Underperform’ by the firm. On Jan 20, 2017, JP Morgan said it Downgrades its rating on Teva Pharmaceutical Industries Ltd (ADR). The shares have been rated ‘Neutral’ by the firm.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) shares turned negative on Wednesdays trading session with the shares closing down -0.68 points or -1.86% at a volume of 69,33,471. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $36.69. The peak price level was also seen at $36.69 while the days lowest was $35.96. Finally the shares closed at $35.97. The 52-week high of the shares is $59.345 while the 52-week low is $31.9. According to the latest information available, the market cap of the company is $36,509 M.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company’s generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines which manufactures and sells generic pharmaceutical products in several dosage forms including tablets capsules injectables inhalants liquids ointments and creams and Specialty medicines which delivers solutions to patients and providers via medicines devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda Trisenox Granix Synribo Lonquex Tevagrastim/Ratiograstim Myocet Trisenox and Eporatio. Its women’s health portfolio includes ParaGard Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.